Federal Register: January 30, 2007 (Volume 72, Number 19)
DOCID: fr30ja07-72 FR Doc E7-1415
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket ID: [Docket No. 2006N-0421]
DOCUMENT ACTION: Notice.
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biological Products: Reporting of Biological Product Deviations in Manufacturing; Forms FDA 3486 and 3486A
DATES: Fax written comments on the collection of information by March 1, 2007.
The Food and Drug Administration (FDA) is announcing that a proposed collection of
information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Agency information collection activities; proposals, submissions, and approvals,
In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for review and clearance.
Biological Products: Reporting of Biological Product Deviations in Manufacturing; Forms FDA 3486 and 3486A (OMB Control Number 0910 0458)Extension
Under section 351 of the Public Health Service Act (42 U.S.C. 262), all biological products, including human blood and blood components, offered for sale in interstate commerce must be licensed and meet standards designed to ensure the continued safety, purity, and potency of such products. In addition, the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 351) provides that drugs and devices (including human blood and blood components) are adulterated if they do not conform with Current Good Manufacturing Practice (CGMP) assuring that they meet the requirements of the act. All establishments manufacturing biological products including human blood and blood components must comply with the applicable CGMP regulations (parts 211, 606, and 820 (21 CFR parts 211, 606, and 820)). Transfusion services are required under 42 CFR 493.1271 to comply with 21 CFR parts 606 and 640 as they pertain to the performance of manufacturing activities. FDA regards biological product deviation (BPD) reporting to be an essential tool in its directive to protect public health by establishing and maintaining surveillance programs that provide timely and useful information.
Section 600.14 requires the manufacturer who holds the biological product license, for other than human blood and blood components, and who had control over the product when the deviation occurred, to report to the Center for Biologics Evaluation and Research (CBER) or to the Center for Drugs Evaluation and Research (CDER) as soon as possible but not to exceed 45 calendar days after acquiring information reasonably suggesting that a reportable event has occurred. Section 606.171 requires a licensed manufacturer of human blood and blood components, including Source Plasma; an unlicensed registered blood establishment; or a transfusion service who had control over the product when the deviation occurred, to report to CBER as soon as possible but not to exceed 45 calendar days after acquiring information reasonably suggesting that a reportable event has occurred. The BPD reporting under 21 CFR 1271.350(b) for human cells, tissues, and cellular and tissuebased products is approved under OMB control number 09100559 (expires November 30, 2007). Form FDA 3486 is used to submit BPDs under these regulations.
Respondents to this collection of information are the licensed manufacturers of biological products other than human blood and blood components, licensed manufacturers of blood and blood components including Source Plasma, unlicensed registered blood establishments, and transfusion services. Based on information from FDA's database, there are an estimated 147 licensed manufacturers of biological products other than human blood and blood components, 194 licensed manufacturers of human blood and blood components, including Source Plasma, and 1,230 unlicensed registered blood establishments. Based on the Center for Medicare and Medicaid Services records, there are an estimated 4,980 transfusion services. The number of licensed manufacturers and total annual responses under Sec. 600.14 include the estimates for both CBER and CDER. The number of total annual responses is based on the number of BPD reports FDA received in fiscal year 2005. The rate of submission is not expected to change significantly in the next few years. Based on information from industry, the estimated average time to complete a deviation report is 2 hours. The availability of the standardized report form, Form FDA 3486, and the ability to submit this report electronically to CBER (CDER does not currently accept electronic filings) further streamlines the report submission process.
CBER is developing an addendum to Form FDA 3486. The webbased addendum (Form FDA 3486A) would request additional information when a BPD report has been reviewed by FDA and evaluated as a possible recall. The additional information requested would include information not contained in the Form FDA 3486 such as: (1) Distribution pattern, (2) method of consignee notification, (3) consignee(s) of products for further manufacture, (4) additional product information, and (5) updated product disposition. This information would be requested by CBER through email notification to the submitter of the BPD report. This information would be used by CBER for purposes of recall classification. We plan to use Form FDA 3486A for only biological products regulated by CBER. We do not plan to use this form for biological products regulated by CDER because they receive very few BPD reports and do not accept electronic filings. CBER estimates that 5 percent of the total BPD reports submitted to CBER would need additional information submitted in the addendum. CBER estimates it would take between 15 to 45 minutes to complete the addendum. For calculation purposes, CBER is using onehalf hour.
Activities such as investigating, changing standard operating procedures or processes, and followup are currently required under part 211 (approved under OMB control no. 09100139, expires September 30, 2008); part 606 (approved under OMB control no. 09100116, expires December 31, 2008); and part 820 (approved under OMB control no. 0910 0073, expires September 30, 2007) and, therefore, are not included in the burden calculation for the separate requirement of submitting a BPD report to FDA.
In the Federal Register of October 31, 2006, (71 FR 63772), FDA published a 60day notice requesting public comment on the information collection provisions. No comments were received.
FDA estimates the burden of this collection of information as follows:
Table 1.Estimated Annual Reporting Burden \1\ FDA Form No. of Annual Frequency Total Annual Hours per 21 CFR Section Number Respondents per Response Responses Responses Total Hours 600.14 3486 147 2.73 401 2.0 802 606.171 \2\ 3486 194 169.89 32,958 2.0 65,916 606.171 \3\ 3486 6,210 1.50 9,311 2.0 18,622 3486A \4\ 6,551 0.33 2,133 0.5 1,067 Total .............. ................. ................. ................. ................. 86,407 \1\ There are no capital costs or maintenance costs associated with this collection of information. \2\ Licensed manufacturers of human blood and blood components, including Source Plasma. \3\ Unlicensed registered blood establishments and transfusion services (1,230 + 4,980 = 6,210). \4\ Five percent of the total annual responses to CBER (42,653 x 0.05 = 2,133).
Dated: January 24, 2007.
Assistant Commissioner for Policy.
[FR Doc. E71415 Filed 12907; 8:45 am]
BILLING CODE 416001S
FOR FURTHER INFORMATION CONTACT
Jonna Capezzuto, Office of the Chief Information Officer (HFA250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857,3018274659.